Identified in 1973, somatostatin (SST) is a cyclic hormone peptide with a short biological half-
life. Somatostatin receptors (SSTRs) are widely expressed in the whole body, with five …

Receptor targeting with radiolabeled peptides has become an important topic, particularly in
nuclear oncology. Strong research efforts are under way in radiopharmaceutical science …

Overexpressed neuropeptide receptors allow tumor visualization using eg radiolabeled
peptidic receptor ligands and positron emission tomography (PET) or single photon …

Molecular imaging plays an essential role in balancing the clinical benefits and risks of
radionuclide-based cancer therapy. To effectively treat individual patients, careful …

The diagnosis of neuroendocrine tumours (NETs) and monitoring of therapy in many
patients relies mainly on morphological imaging techniques such as computed tomography …

Four open chain tetraamine-functionalized bombesin (BB) analogues were synthesized
[parent tetradecapeptide-based Demobesin 3 and 4 and BB (7− 14)-based Demobesin 5 …

Despite the advances in molecular biology and biochemistry, the prognosis of patients
suffering from tumor diseases remains poor. The limited therapeutic success can be …

Carcinoid tumors are rare, often insidious neoplasms arising from neuroendocrine cells. The
majority arise in the gastrointestinal system, and are often incidentally found during …

The clinical success of radiolabeled somatostatin analogs in the diagnosis and therapy—
“theranostics”—of tumors expressing the somatostatin subtype 2 receptor (SST2R) has …

Purpose At all stages of the disease, serious difficulties are encountered in the imaging
diagnosis of carcinoids. Somatostatin receptor scintigraphy (SRS) holds great promise for …